Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Heather Ann Mcsharry Sells 3,415 Shares

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Heather Ann Mcsharry sold 3,415 shares of the business’s stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $177.78, for a total value of $607,118.70. Following the completion of the sale, the director owned 20,449 shares of the company’s stock, valued at approximately $3,635,423.22. This trade represents a 14.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock traded up $3.97 during mid-day trading on Monday, reaching $180.90. 2,027,413 shares of the company were exchanged, compared to its average volume of 952,323. The firm has a market cap of $10.99 billion, a PE ratio of -26.88, a PEG ratio of 8.49 and a beta of 0.29. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37. The company has a fifty day simple moving average of $138.86 and a 200-day simple moving average of $122.58. Jazz Pharmaceuticals PLC has a 12 month low of $95.49 and a 12 month high of $182.99.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Wednesday, November 5th. The specialty pharmaceutical company reported $8.13 earnings per share for the quarter, beating analysts’ consensus estimates of $5.87 by $2.26. The firm had revenue of $1.13 billion during the quarter, compared to the consensus estimate of $1.11 billion. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The company’s revenue was up 6.7% compared to the same quarter last year. During the same period in the prior year, the company posted $6.54 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 7.650-8.450 EPS. As a group, equities research analysts expect that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of Jazz Pharmaceuticals in a research note on Wednesday, October 8th. Wall Street Zen raised shares of Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, November 8th. JPMorgan Chase & Co. reduced their price target on shares of Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating on the stock in a research report on Monday, October 27th. Needham & Company LLC restated a “buy” rating and set a $202.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, August 28th. Finally, Zacks Research upgraded Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Friday, August 15th. Thirteen equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $195.67.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. EverSource Wealth Advisors LLC grew its holdings in shares of Jazz Pharmaceuticals by 9.0% during the third quarter. EverSource Wealth Advisors LLC now owns 983 shares of the specialty pharmaceutical company’s stock worth $130,000 after purchasing an additional 81 shares during the last quarter. Tectonic Advisors LLC boosted its position in Jazz Pharmaceuticals by 1.5% during the 3rd quarter. Tectonic Advisors LLC now owns 5,626 shares of the specialty pharmaceutical company’s stock worth $742,000 after buying an additional 82 shares during the period. Teacher Retirement System of Texas grew its holdings in Jazz Pharmaceuticals by 0.6% during the 2nd quarter. Teacher Retirement System of Texas now owns 15,560 shares of the specialty pharmaceutical company’s stock worth $1,651,000 after acquiring an additional 90 shares during the last quarter. Fairbanks Capital Management Inc. grew its holdings in Jazz Pharmaceuticals by 0.4% during the 3rd quarter. Fairbanks Capital Management Inc. now owns 25,023 shares of the specialty pharmaceutical company’s stock worth $3,298,000 after acquiring an additional 94 shares during the last quarter. Finally, Generali Investments Towarzystwo Funduszy Inwestycyjnych increased its position in Jazz Pharmaceuticals by 8.7% in the 2nd quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 1,250 shares of the specialty pharmaceutical company’s stock valued at $133,000 after acquiring an additional 100 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.